RESUMO
Our objective was to evaluate the frequency of antinucleosome antibodies (anti-Ncs) in juvenile systemic lupus erythematosus (JSLE) comparing it to that observed for anti-DNA and to correlate the presence of these antibodies with clinical manifestations and disease activity. Anti-Ncs and anti-DNA were detected by ELISA in 74 patients with JSLE and 64 normal controls. Clinical records were reviewed. Disease activity was assessed by SLEDAI score. Anti-Ncs and anti-DNA showed sensitivity of 52.7% and 54% and specificity of 98.4% and 95.3%, respectively. Disagreement between the two assays was found in 25.7% of the cases: isolated positive Anti-Ncs in nine cases (12.2%) and isolated positive anti-DNA in 10 cases (13.5%). Agreement was found in 74.3%: both positive antibodies in 30 cases and both negative in 25. The presence of anti-Ncs was significantly associated with malar erythema, hemolytic anemia, anti-DNA and low complement levels, but not with renal manifestations. The presence of anti-Ncs was associated with a higher SLEDAI median (P < 0.001) and its titers correlated with the SLEDAI score (r = 0.504; P < 0.001). The frequency, sensitivity and specificity values were similar between anti-Ncs and anti-DNA antibodies in patients with JSLE. Nevertheless, the discordance of 25.7% between the two assays suggests that both antibodies may have a complementary diagnostic role. The association and correlation between anti-Ncs and several disease activity parameters demonstrated its usufulness in the follow-up of these patients.
Assuntos
Anticorpos Antinucleares/imunologia , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/imunologia , Nucleossomos/imunologia , Adolescente , Anticorpos Antinucleares/sangue , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Lúpus Eritematoso Sistêmico/fisiopatologia , Masculino , Estatística como AssuntoAssuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Farmacorresistência Viral , HIV-1/genética , Síndrome da Imunodeficiência Adquirida/virologia , Brasil , Genótipo , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , HIV-1/classificação , Humanos , Mutação , Falha de TratamentoRESUMO
OBJECTIVES: To investigate the serum levels of VEGF in patients with rheumatoid arthritis of long duration. METHODS: Serum VEGF levels were measured in 118 patients with long-standing rheumatoid arthritis according to the ACR criteria (mean duration 12 years). The disease activity score was evaluated by the method of van der Heijde et al. RESULTS: Serum levels of VEGF in patients with RA were significantly higher than in healthy controls. VEGF levels showed no correlation with CRP, SAA amyloid protein, or the disease activity score. CONCLUSIONS: Our findings suggest that, contrary to the results reported in patients with early onset RA, where VEGF appears to play an active part in joint inflammation, in long-standing RA elevated VEGF serum levels may be an independent marker although its significance remain to be established.
Assuntos
Artrite Reumatoide/sangue , Fatores de Crescimento Endotelial/sangue , Linfocinas/sangue , Adulto , Amiloide/sangue , Artrite Reumatoide/fisiopatologia , Biomarcadores/sangue , Proteína C-Reativa/análise , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio VascularAssuntos
Artroscopia , Cartilagem/metabolismo , Glicoproteínas/sangue , Osteoartrite do Joelho/sangue , Adipocinas , Adulto , Biomarcadores/sangue , Cartilagem/patologia , Proteína 1 Semelhante à Quitinase-3 , Condrócitos/metabolismo , Diagnóstico Diferencial , Feminino , Fibroblastos/metabolismo , Glicoproteínas/metabolismo , Humanos , Lectinas , Masculino , Pessoa de Meia-Idade , Osteoartrite do Joelho/patologia , Osteoartrite do Joelho/cirurgia , Líquido Sinovial/citologiaAssuntos
Centros Médicos Acadêmicos/legislação & jurisprudência , Indigência Médica/legislação & jurisprudência , Programas Nacionais de Saúde/legislação & jurisprudência , Garantia da Qualidade dos Cuidados de Saúde/legislação & jurisprudência , Centros Médicos Acadêmicos/economia , Brasil , Economia Hospitalar/legislação & jurisprudência , Financiamento Governamental/legislação & jurisprudência , Humanos , Indigência Médica/economia , Programas Nacionais de Saúde/economiaRESUMO
OBJECTIVE: Adult onset Still's disease (AOSD) is an inflammatory disorder with elevated serum acute phase proteins. Interleukin-6 is a major contributor to the acute phase response. We therefore examined the serum levels of CRP, SAA and interleukin-6 in active and inactive AOSD. RESULTS: Active patients had significantly elevated CRP, SAA, and interleukin-6 values. After steroid treatment a marked reduction was observed in all three parameters. There was a close kinetics on the fluctuations of CRP and SAA, but not on IL-6. CONCLUSION: Acute phase proteins and IL-6 are useful markers of disease activity in AOSD.
Assuntos
Biomarcadores/sangue , Interleucina-6/sangue , Doença de Still de Início Tardio/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Apolipoproteínas/metabolismo , Proteína C-Reativa/metabolismo , Ensaio de Imunoadsorção Enzimática , Humanos , Pessoa de Meia-Idade , Proteína Amiloide A Sérica/metabolismoRESUMO
Recent data suggest that the clinical course of reactional states in leprosy is closely related to the cytokine profile released locally or systemically by the patients. In the present study, patients with erythema nodosum leprosum (ENL) were grouped according to the intensity of their clinical symptoms. Clinical and immunological aspects of ENL and the impact of these parameters on bacterial load were assessed in conjunction with patients' in vitro immune response to mycobacterial antigens. In 10 out of the 17 patients tested, BI (bacterial index) was reduced by at least 1 log from leprosy diagnosis to the onset of their first reactional episode (ENL), as compared to an expected 0.3 log reduction in the unreactional group for the same MDT (multidrug therapy) period. However, no difference in the rate of BI reduction was noted at the end of MDT among ENL and unreactional lepromatous patients. Accordingly, although TNF-alpha (tumor necrosis factor) levels were enhanced in the sera of 70.6% of the ENL patients tested, no relationship was noted between circulating TNF-alpha levels and the decrease in BI detected at the onset of the reactional episode. Evaluation of bacterial viability of M. leprae isolated from the reactional lesions showed no growth in the mouse footpads. Only 20% of the patients demonstrated specific immune response to M. leprae during ENL. Moreover, high levels of soluble IL-2R (interleukin-2 receptor) were present in 78% of the patients. Circulating anti-neural (anti-ceramide and anti-galactocerebroside antibodies) and anti-mycobacterial antibodies were detected in ENL patients' sera as well, which were not related to the clinical course of disease. Our data suggest that bacterial killing is enhanced during reactions. Emergence of specific immune response to M. leprae and the effective role of TNF-alpha in mediating fragmentation of bacteria still need to be clarified.
Assuntos
Eritema Nodoso/imunologia , Hanseníase Virchowiana/imunologia , Mycobacterium leprae/crescimento & desenvolvimento , Receptores de Interleucina-2/sangue , Adolescente , Adulto , Idoso , Animais , Contagem de Colônia Microbiana , Eritema Nodoso/sangue , Eritema Nodoso/microbiologia , Feminino , Humanos , Interferon gama/sangue , Hanseníase Virchowiana/sangue , Hanseníase Virchowiana/microbiologia , Masculino , Camundongos , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/análiseRESUMO
Our objective was to assess the prevalence of autoantibodies in patients with leprosy. Forty-one cases of lepromatous leprosy were studied. For the detection of autoantibodies we used the Elisa technique using the following purified antigens in an Elisa assay: dsDNA, ssDNA, histone, mitochondria, RNA, RNP, SS-A, SS-B, Sm, Scl-70, Anca C, Anca P and the cardiolipin complex. As a "cut off" point we used values shown on previous studies to differentiate normal from elevated values. Antibodies to SS-B, mitochondria and cardiolipin were the most prevalent in our study. Antimitochondrial antibodies distinct from those seen in primary biliary cirrhosis and antiphospholipid antibodies with variable ligand activity to B2GIP are frequent in the sera of leprosy patients.
Assuntos
Autoanticorpos/sangue , Hanseníase/imunologia , Autoanticorpos/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , PrevalênciaRESUMO
Serum samples were analysed for interleukin-2 receptors levels (sIL-2R) in 26 patients with definite multiple sclerosis as defined by Poser and col. Three groups of patients form the basis of this study: group I, with 14 patients with clinical evidence of active disease; group II, with 12 patients with clinically stable multiple sclerosis; and group III, with 8 patients with other neurological diseases. Blood was collected by venipuncture and centrifuged. All samples were stored at -20 degrees C until testing. The assay used monoclonal antibodies against epitopes of interleukin-2 receptors. In the wells of a microtiter plate coated with anti-soluble interleukin-2 receptors (Immunotech SA) samples to be measured or standards are incubated in the presence of a second monoclonal antibody conjugated with alkaline phosphatase. The amount of bound enzyme-conjugate is measured by adding a chromogenic substrate. The intensity of the resulting colour is proportional to the sIL-2R concentration present in the sample. Increased serum levels of sIL-2R were found in 7 of 14 patients with active multiple sclerosis (50%), in only 1 of the 12 patients with clinically stable multiple sclerosis and in none of the patients with other neurological diseases.
Assuntos
Esclerose Múltipla/sangue , Receptores de Interleucina-2/análise , Adolescente , Adulto , Feminino , Humanos , Ativação Linfocitária/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Receptores de Interleucina-2/fisiologia , Linfócitos T/metabolismoAssuntos
Autoanticorpos/análise , Autoantígenos/imunologia , Cirrose Hepática Biliar/imunologia , Complexo Piruvato Desidrogenase/imunologia , Eletroforese em Gel de Poliacrilamida , Ensaio de Imunoadsorção Enzimática , Hanseníase Virchowiana/imunologia , Immunoblotting , Mitocôndrias Hepáticas/enzimologia , Mitocôndrias Hepáticas/imunologia , Peso MolecularRESUMO
Uveitis is a manifestation of various chronic inflammatory arthritic conditions. There are considerable data implicating abnormalities of immune function in the etiopathogenesis of uveitis. We evaluated the percentage of cells expressing interleukin 2 (IL-2) receptor (membrane bound) and the levels of soluble IL-2 in the blood and aqueous humor of patients in various rheumatic diseases and acute untreated uveitis. Our findings showed increased IL-2 receptors (IL-2R) and soluble IL-2 receptors on the aqueous humor of patients with uveitis when compared to healthy controls. These results suggest an immunoregulatory role of IL-2R in acute uveitis and raises the possibility that its detection may be useful in management.
Assuntos
Humor Aquoso/química , Receptores de Interleucina-2/análise , Uveíte/metabolismo , Ensaio de Imunoadsorção Enzimática , Imunofluorescência , Humanos , Solubilidade , Linfócitos T/química , Linfócitos T/patologia , Linfócitos T/ultraestrutura , Uveíte/sangue , Uveíte/patologiaRESUMO
We studied the levels of membrane-bound and soluble-form interleukin 2 (IL-2) receptors in forty patients with rheumatoid arthritis. Levels of IL-2 receptors in the sera and synovial fluid of patients with rheumatoid arthritis were elevated when compared to values observed in normal sera and synovial fluid derived from the osteoarthritic joint. Simultaneous elevation of IL-2 receptor expression in blood and synovial fluid lymphoid cells was also detected, but no correlation was found between the two parameters nor between serum IL-2 receptor levels and the hemosedimentation rate. We conclude that measurement of serum concentrations of soluble IL-2 receptors should be used with caution as an index of disease activity, but may be useful when used in conjunction with other parameters in the management of patients with rheumatoid arthritis.
Assuntos
Artrite Reumatoide/metabolismo , Receptores de Interleucina-2/metabolismo , Líquido Sinovial/metabolismo , Artrite Reumatoide/sangue , Humanos , Membranas/metabolismo , Valores de Referência , SolubilidadeRESUMO
1. We have shown that nonsteroidal anti-inflammatory drugs are potent inhibitors of neutrophil activation. Tenoxicam is a new compound of the oxicam family which has been shown to be effective for routine clinical use. 2. In the present study we examined the immune pharmacological effects of this compound on lymphocyte function by determining its effect on the expression of IL-2 receptors, on monocyte function by looking at chemotaxis and IL-1 release and on neutrophil function by evaluating the chemotactic response to a standard stimulus. 3. The data show that Tenoxicam inhibits the neutrophil and monocyte functional chemotactic response in vitro, and to some extent in vivo for monocytes, but has no effect on the expression of IL-2 receptors or IL-1 release. Tenoxicam inhibits the mobilization of neutrophils and monocytes to inflammatory sites, even though this effect was not clearly demonstrable when cells were tested after oral use.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Linfócitos/efeitos dos fármacos , Monócitos/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Piroxicam/análogos & derivados , Receptores de Interleucina-2/metabolismo , Quimiotaxia/efeitos dos fármacos , Humanos , Técnicas In Vitro , Linfócitos/metabolismo , Monócitos/metabolismo , Neutrófilos/metabolismo , Piroxicam/farmacologiaRESUMO
The authors present an evaluation of sixty patients with SLE who were observed at the "Arnaldo Vieira de Carvalho" Cancer Institute from 1980 to 1988. Their findings were compared to findings of other international series. Some differences were observed in the frequency of clinical manifestations, laboratory findings, and mortality.
Assuntos
Lúpus Eritematoso Sistêmico , Adolescente , Adulto , Idoso , Brasil , Institutos de Câncer , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/mortalidade , Masculino , Pessoa de Meia-Idade , PrognósticoRESUMO
1. We have shown that nonsteroidal anti-inflammatory drugs are potent inhibitors of neutrophil activation. tenoxican is a new compound of the oxican family which has been shown to be effective for routine clinical use. 2. In the present study we examined the immune pharmacological effects of this compound on lymphocyte function by determining its efffect on the expression of IL-2 receptors, on monocyte function by looking at chemotaxis and IL-1 release and on release and on neutrophil function by evaluating the chemotactic response to a standard stimulus. 3. The data show that Tenoxican inhibits the neutrophil and monocyte functional chemotactic response in vitro, and to some extent in vivo for monocytes, but has no effect onthe expression of IL-2 receptors or IL-1 release. Tenoxicam inhibits the mobilization of neutrophils and monocytes to inflamatory sites, even thought this effect was not clearly demonstrable when cells were tested after oral use
Assuntos
Humanos , Técnicas In Vitro , Linfócitos/efeitos dos fármacos , Monócitos/efeitos dos fármacos , Neutrófilos , Piroxicam/análogos & derivados , Receptores de Interleucina-2/metabolismo , Quimiotaxia/efeitos dos fármacos , Linfócitos/metabolismo , Monócitos/metabolismo , Neutrófilos/metabolismo , Piroxicam/administração & dosagem , Piroxicam/análogos & derivados , Piroxicam/farmacologiaRESUMO
Patients with multiple sclerosis present changes in lymphocyte subtypes in the peripheral blood. In this study, the authors demonstrate that patients with clinical activity or under an episode show marked increases in the percentages of activate lymphocytes detected through monoclonal antibodies against transferrin and interleukin 2 receptors.